- Home
- AGEN vs FMN Comparison
AGEN vs FMN Comparison
Compare AGEN & FMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- FMN
- Stock Information
- Founded
- AGEN 1994
- FMN 2002
- Country
- AGEN United States
- FMN United States
- Employees
- AGEN N/A
- FMN N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- FMN Investment Managers
- Sector
- AGEN Health Care
- FMN Finance
- Exchange
- AGEN Nasdaq
- FMN Nasdaq
- Market Cap
- AGEN 38.1M
- FMN 86.2M
- IPO Year
- AGEN 2000
- FMN N/A
- Fundamental
- Price
- AGEN $1.61
- FMN $10.92
- Analyst Decision
- AGEN Buy
- FMN
- Analyst Count
- AGEN 4
- FMN 0
- Target Price
- AGEN $8.00
- FMN N/A
- AVG Volume (30 Days)
- AGEN 500.1K
- FMN 22.8K
- Earning Date
- AGEN 05-06-2025
- FMN 01-01-0001
- Dividend Yield
- AGEN N/A
- FMN 3.86%
- EPS Growth
- AGEN N/A
- FMN N/A
- EPS
- AGEN N/A
- FMN N/A
- Revenue
- AGEN $103,463,000.00
- FMN N/A
- Revenue This Year
- AGEN $4.03
- FMN N/A
- Revenue Next Year
- AGEN $5.57
- FMN N/A
- P/E Ratio
- AGEN N/A
- FMN N/A
- Revenue Growth
- AGEN N/A
- FMN N/A
- 52 Week Low
- AGEN $1.44
- FMN $9.09
- 52 Week High
- AGEN $19.69
- FMN $11.31
- Technical
- Relative Strength Index (RSI)
- AGEN 21.45
- FMN 41.31
- Support Level
- AGEN $1.44
- FMN $10.77
- Resistance Level
- AGEN $1.77
- FMN $11.00
- Average True Range (ATR)
- AGEN 0.13
- FMN 0.07
- MACD
- AGEN 0.02
- FMN -0.01
- Stochastic Oscillator
- AGEN 8.00
- FMN 36.00
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About FMN Federated Hermes Premier Municipal Income Fund
Federated Hermes Premier Municipal Income Fund is a United States-based diversified, closed-end management investment company. The investment objective of the fund is to provide current income exempt from federal income tax, including the federal alternative minimum tax by investing in long-term, tax exempt municipal bonds diversified among states, sectors and issuers. Its portfolio of investments comprises different sectors such as hospitals, toll road, senior care, airport, tobacco, and other sectors.